Tandem Diabetes Care (TNDM) Cash from Financing Activities (2013 - 2026)

Tandem Diabetes Care's Cash from Financing Activities history runs 14 years deep, the most recent figure standing at $274.2 million for Q1 2026.

• Quarterly Cash from Financing Activities rose 5948.14% year-over-year to $274.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $235.5 million (up 2476.93% YoY) and the FY2025 annual result came in at -$43.4 million, down 618.31% from the prior year.
• Cash from Financing Activities was $274.2 million for Q1 2026 at Tandem Diabetes Care, up from $2.6 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $274.2 million in Q1 2026 and bottomed at -$39.7 million in Q2 2025.
• A 5-year average of $15.3 million and a median of $2.3 million in 2024 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2025 — Cash from Financing Activities slumped 1222.88% — and 2026, when it jumped 5948.14%.
• Tandem Diabetes Care's Cash from Financing Activities stood at $6.1 million in 2022, then tumbled by 57.1% to $2.6 million in 2023, then slipped by 12.04% to $2.3 million in 2024, then advanced by 13.12% to $2.6 million in 2025, then soared by 10428.46% to $274.2 million in 2026.
• Business Quant data shows TNDM's Cash from Financing Activities at $274.2 million in Q1 2026, $2.6 million in Q4 2025, and -$1.6 million in Q3 2025.